HK Bull/Bear Outstanding Qty Ratio(66:34) | May 6th
As of May 6th, the latest bull-bear ratio of the Hang Seng Index is 66:34.
As of May 6th, the latest bull-bear street cargo ratio of the Hang Seng Index (HSI) is 66:34.
According to the data in the CITIC SEC bull-bear certificate street cargo distribution chart, the heavy cargo area of bear certificates is in the range of 26500-26599, with the latest number of bear certificates in this range being 480, a decrease of 205 from the previous trading day. The most newly added bear certificates are in the range of 26000-26099, with the latest number of bear certificates in this range being 310, an increase of 310 from the previous trading day.
The heavy cargo area of bull certificates is in the range of 25600-25699, with the latest number of bull certificates in this range being 1280, an increase of 242 from the previous trading day. The most newly added bull certificates are in the range of 25200-25299, with the latest number of bull certificates in this range being 1153, an increase of 377 from the previous trading day.
Related Articles

Zhongtai releases an overview of the financial reports of 42 banks for 2025 and the first quarter of 2026: high relationship with the economic model, interest rate bottoming out stabilizing revenue surpassing expectations.

Arista Networks (ANET.US) reported Q1 revenue above expectations, with gross margins slightly lower than expected, causing the stock to drop over 10% after hours.

SIMCERE PHARMA (02096)SIM0613 (LRRC15 antibody drug conjugate) has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.
Zhongtai releases an overview of the financial reports of 42 banks for 2025 and the first quarter of 2026: high relationship with the economic model, interest rate bottoming out stabilizing revenue surpassing expectations.

Arista Networks (ANET.US) reported Q1 revenue above expectations, with gross margins slightly lower than expected, causing the stock to drop over 10% after hours.

SIMCERE PHARMA (02096)SIM0613 (LRRC15 antibody drug conjugate) has obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.






